Home > Topical pan-JAK inhibitor achieved efficacy and fast onset in chronic hand eczema

Topical pan-JAK inhibitor achieved efficacy and fast onset in chronic hand eczema

Presented By
Prof. Margitta Worm, Charité Universitätsmedizin Berlin, Germany
Conference
EADV 2020
The topical pan-JAK inhibitor delgocitinib showed remarkable efficacy and a fast onset of action in hand eczema, an indication with a high medical need [1]. Hand eczema is characterised by painful, pruritic, non-infectious inflammatory skin changes on the hands and wrist. The disease is considered chronic when it is lasting ≥3 months or relapsing at least twice a year. Current treatment options are limited to emollients, topical corticosteroids, and calcineurin inhibitors. The topical pan-JAK inhibitor delgocitinib prevents inflammation by blocking several cytokine-mediated signalling cascades involved in the pathophysiology of chronic hand eczema. This explains the motivation for the phase 2b, dose-finding study in chronic hand eczema patients assessing the safety and efficacy of this agent. Participants (n=258) were randomised to delgocitinib cream in 4 different doses (i.e. 1 mg/g, 3 mg/g, 8 mg/g, and 20 mg/g) or a vehicle cream. All treatments w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on